{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,14]],"date-time":"2026-09-14T12:17:44Z","timestamp":1789388264175,"version":"build-2803163510"},"reference-count":76,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2017,10,1]],"date-time":"2017-10-01T00:00:00Z","timestamp":1506816000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":["clinicalkey.jp","clinicalkey.com","clinicalkey.es","clinicalkey.com.au","clinicalkey.fr","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Cancer Epidemiology"],"published-print":{"date-parts":[[2017,10]]},"DOI":"10.1016\/j.canep.2017.08.012","type":"journal-article","created":{"date-parts":[[2017,9,2]],"date-time":"2017-09-02T05:33:22Z","timestamp":1504330402000},"page":"113-124","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":19,"special_numbering":"PA","title":["Calcium channel blockers and breast cancer incidence: An updated systematic review and meta-analysis of the evidence"],"prefix":"10.1016","volume":"50","author":[{"given":"Cameron M.","family":"Wright","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rachael E.","family":"Moorin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Enayet K.","family":"Chowdhury","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bruno H.","family":"Stricker","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christopher M.","family":"Reid","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christobel M.","family":"Saunders","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jeffery D.","family":"Hughes","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.canep.2017.08.012_bib0005","series-title":"Guidelines for the Diagnosis and Management of Hypertension in Adults [Internet]","author":"National Heart Foundation of Australia (Heart Foundation)","year":"2016"},{"key":"10.1016\/j.canep.2017.08.012_bib0010","series-title":"Australian Statistics on Medicine 2015 [Internet]","author":"Australian Government Department of Health (DoH)","year":"2016"},{"issue":"17","key":"10.1016\/j.canep.2017.08.012_bib0015","doi-asserted-by":"crossref","first-page":"1637","DOI":"10.1001\/jamainternmed.2013.9069","article-title":"Calcium-channel blockers and breast cancer: a hypothesis revived","volume":"173","author":"Coogan","year":"2013","journal-title":"JAMA Intern. Med."},{"key":"10.1016\/j.canep.2017.08.012_bib0020","series-title":"Cancer in Australia: An Overview in 2017 [Internet]","author":"Australian Institute for Health and Welfare (AIHW)","year":"2017"},{"issue":"8","key":"10.1016\/j.canep.2017.08.012_bib0025","doi-asserted-by":"crossref","first-page":"e800","DOI":"10.1200\/JOP.2016.011742","article-title":"Nonadherence to oral medications for chronic conditions in Breast cancer survivors","volume":"12","author":"Yang","year":"2016","journal-title":"J Oncol Pract"},{"issue":"7","key":"10.1016\/j.canep.2017.08.012_bib0030","doi-asserted-by":"crossref","first-page":"1857","DOI":"10.1016\/S0735-1097(99)00447-7","article-title":"Calcium channel blockers, apoptosis and cancer: is there a biologic relationship?","volume":"34","author":"Mason","year":"1999","journal-title":"J. Am. Coll. Cardiol."},{"issue":"5117","key":"10.1016\/j.canep.2017.08.012_bib0035","doi-asserted-by":"crossref","first-page":"86","DOI":"10.1126\/science.7686306","article-title":"Increased activity of L-type Ca2+ channels exposed to serum from patients with type I diabetes","volume":"261","author":"Juntti-Berggren","year":"1993","journal-title":"Science"},{"issue":"2","key":"10.1016\/j.canep.2017.08.012_bib0040","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1002\/pros.2990130204","article-title":"Calcium channel antagonists delay regression of androgen-dependent tissues and suppress gene activity associated with cell death","volume":"13","author":"Connor","year":"1988","journal-title":"Prostate"},{"issue":"2","key":"10.1016\/j.canep.2017.08.012_bib0045","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1002\/pros.2990130203","article-title":"Activation of a Ca2+-Mg2+-dependent endonuclease as an early event in castration-induced prostatic cell death","volume":"13","author":"Kyprianou","year":"1988","journal-title":"Prostate"},{"issue":"2","key":"10.1016\/j.canep.2017.08.012_bib0050","doi-asserted-by":"crossref","first-page":"331","DOI":"10.1161\/01.ATV.17.2.331","article-title":"Oxidized LDLs induce massive apoptosis of cultured human endothelial cells through a calcium-dependent pathway Prevention by aurintricarboxylic acid","volume":"17","author":"Escargueil-Blanc","year":"1997","journal-title":"Arterioscler. Thromb. Vasc. Biol."},{"issue":"6","key":"10.1016\/j.canep.2017.08.012_bib0055","first-page":"1265","article-title":"Apoptosis of vascular smooth muscle cells: protein kinase C and oncoprotein Bcl-2 are involved in regulation of apoptosis in non-transformed rat vascular smooth muscle cells","volume":"145","author":"Leszczynski","year":"1994","journal-title":"Am. J. Pathol."},{"issue":"16","key":"10.1016\/j.canep.2017.08.012_bib0060","doi-asserted-by":"crossref","first-page":"6421","DOI":"10.1073\/pnas.86.16.6421","article-title":"Role of Ca2+ channels in the ability of membrane depolarization to prevent neuronal death induced by trophic-factor deprivation: evidence that levels of internal Ca2+ determine nerve growth factor dependence of sympathetic ganglion cells","volume":"86","author":"Koike","year":"1989","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"issue":"2","key":"10.1016\/j.canep.2017.08.012_bib0065","doi-asserted-by":"crossref","first-page":"1172","DOI":"10.1523\/JNEUROSCI.15-02-01172.1995","article-title":"Apoptosis in cerebellar granule cells is blocked by high KCl, forskolin, and IGF-1 through distinct mechanisms of action: the involvement of intracellular calcium and RNA synthesis","volume":"15","author":"Galli","year":"1995","journal-title":"The J. Neurosci."},{"issue":"1","key":"10.1016\/j.canep.2017.08.012_bib0070","doi-asserted-by":"crossref","first-page":"122","DOI":"10.1006\/taap.1996.0150","article-title":"Calcium channel blockers induce thymic apoptosis in vivo in rats","volume":"139","author":"Balakumaran","year":"1996","journal-title":"Toxicol. Appl. Pharmacol."},{"issue":"25","key":"10.1016\/j.canep.2017.08.012_bib0075","doi-asserted-by":"crossref","first-page":"2983","DOI":"10.1161\/CIRCULATIONAHA.112.117333","article-title":"Body mass index and risk of incident hypertension over the life course: the Johns Hopkins Precursors Study","volume":"126","author":"Shihab","year":"2012","journal-title":"Circulation"},{"issue":"Suppl. 2","key":"10.1016\/j.canep.2017.08.012_bib0080","doi-asserted-by":"crossref","first-page":"S77","DOI":"10.1038\/bjc.2011.489","article-title":"The fraction of cancer attributable to lifestyle and environmental factors in the UK in 2010","volume":"105","author":"Parkin","year":"2011","journal-title":"Br. J. Cancer"},{"issue":"5","key":"10.1016\/j.canep.2017.08.012_bib0085","doi-asserted-by":"crossref","first-page":"1242","DOI":"10.1161\/01.HYP.37.5.1242","article-title":"Alcohol consumption and the incidence of hypertension: the Atherosclerosis Risk in Communities Study","volume":"37","author":"Fuchs","year":"2001","journal-title":"Hypertension"},{"issue":"3","key":"10.1016\/j.canep.2017.08.012_bib0090","doi-asserted-by":"crossref","first-page":"204","DOI":"10.1093\/alcalc\/ags011","article-title":"Epidemiology and pathophysiology of alcohol and breast cancer: update 2012","volume":"47","author":"Seitz","year":"2012","journal-title":"Alcohol Alcohol."},{"key":"10.1016\/j.canep.2017.08.012_bib0095","series-title":"Cochrane Handbook for Systematic Review of Interventions Version 5.1.0 [updated March 2011] [Internet]","author":"Higgins","year":"2011"},{"issue":"7","key":"10.1016\/j.canep.2017.08.012_bib0100","doi-asserted-by":"crossref","first-page":"e1000097","DOI":"10.1371\/journal.pmed.1000097","article-title":"Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement","volume":"6","author":"Moher","year":"2009","journal-title":"PLoS Med."},{"issue":"7","key":"10.1016\/j.canep.2017.08.012_bib0105","doi-asserted-by":"crossref","first-page":"711","DOI":"10.1002\/pds.3645","article-title":"Association between calcium channel blockers and breast cancer: a meta-analysis of observational studies","volume":"23","author":"Chen","year":"2014","journal-title":"Pharmacoepidemiol. Drug Saf."},{"issue":"9","key":"10.1016\/j.canep.2017.08.012_bib0110","doi-asserted-by":"crossref","first-page":"e105801","DOI":"10.1371\/journal.pone.0105801","article-title":"Calcium channel blockers and risk of breast cancer: a meta-analysis of 17 observational studies","volume":"9","author":"Li","year":"2014","journal-title":"PLoS One"},{"key":"10.1016\/j.canep.2017.08.012_bib0115","series-title":"University of York, Centre for Reviews and Dissemination (CRD). PROSPERO Homepage [Internet]","year":"2015"},{"key":"10.1016\/j.canep.2017.08.012_bib0120","series-title":"WHO Collaborating Centre for Drug Statistic Methodology. ATC\/DDD Index 2015 [Internet]","year":"2015"},{"issue":"10","key":"10.1016\/j.canep.2017.08.012_bib0125","doi-asserted-by":"crossref","first-page":"e297","DOI":"10.1371\/journal.pmed.0040297","article-title":"Strengthening the reporting of observational studies in epidemiology (STROBE): explanation and elaboration","volume":"4","author":"Vandenbroucke","year":"2007","journal-title":"PLoS Med."},{"issue":"3","key":"10.1016\/j.canep.2017.08.012_bib0130","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1016\/0197-2456(86)90046-2","article-title":"Meta-analysis in clinical trials","volume":"7","author":"DerSimonian","year":"1986","journal-title":"Control. Clin. Trials"},{"issue":"7414","key":"10.1016\/j.canep.2017.08.012_bib0135","doi-asserted-by":"crossref","first-page":"557","DOI":"10.1136\/bmj.327.7414.557","article-title":"Measuring inconsistency in meta-analyses","volume":"327","author":"Higgins","year":"2003","journal-title":"BMJ"},{"issue":"7109","key":"10.1016\/j.canep.2017.08.012_bib0140","doi-asserted-by":"crossref","first-page":"629","DOI":"10.1136\/bmj.315.7109.629","article-title":"Bias in meta-analysis detected by a simple, graphical test","volume":"315","author":"Egger","year":"1997","journal-title":"BMJ"},{"issue":"3","key":"10.1016\/j.canep.2017.08.012_bib0145","doi-asserted-by":"crossref","first-page":"395","DOI":"10.1177\/1536867X1001000307","article-title":"Reeves D metaan: random effects meta-analysis","volume":"10","author":"Kontopantelis","year":"2010","journal-title":"Stata J."},{"key":"10.1016\/j.canep.2017.08.012_bib0150","series-title":"Assessing Risk of Bias and Confounding in Observational Studies of Interventions or Exposures: Further Development of the RTI Item Bank. AHRQ Methods for Effective Health Care","author":"Viswanathan","year":"2013"},{"key":"10.1016\/j.canep.2017.08.012_bib0155","series-title":"The Newcastle-Ottawa Scale (NOS) for Assessing the Quality of Nonrandomised Studies in Meta-.Analyses [Internet]","author":"Wells","year":"2014"},{"issue":"7650","key":"10.1016\/j.canep.2017.08.012_bib0160","doi-asserted-by":"crossref","first-page":"924","DOI":"10.1136\/bmj.39489.470347.AD","article-title":"GRADE: an emerging consensus on rating quality of evidence and strength of recommendations","volume":"336","author":"Guyatt","year":"2008","journal-title":"BMJ"},{"issue":"12","key":"10.1016\/j.canep.2017.08.012_bib0165","doi-asserted-by":"crossref","first-page":"e50893","DOI":"10.1371\/journal.pone.0050893","article-title":"Long-term use of angiotensin receptor blockers and the risk of cancer","volume":"7","author":"Azoulay","year":"2012","journal-title":"PLoS One"},{"issue":"10","key":"10.1016\/j.canep.2017.08.012_bib0170","doi-asserted-by":"crossref","first-page":"1700","DOI":"10.1001\/jamainternmed.2014.3867","article-title":"Breast cancer risk and use of calcium channel blockers using Swedish population registries","volume":"174","author":"Bergman","year":"2014","journal-title":"JAMA Intern. Med."},{"issue":"3","key":"10.1016\/j.canep.2017.08.012_bib0175","doi-asserted-by":"crossref","first-page":"558","DOI":"10.1097\/HJH.0000000000000813","article-title":"Antihypertensive agents and the risk of breast cancer in women aged 55 years and older: a nested case-control study","volume":"34","author":"Chang","year":"2016","journal-title":"J. Hypertens."},{"issue":"5","key":"10.1016\/j.canep.2017.08.012_bib0180","doi-asserted-by":"crossref","first-page":"319","DOI":"10.1007\/s10654-007-9135-0","article-title":"Medication use and the risk of breast cancer","volume":"22","author":"Davis","year":"2007","journal-title":"Eur. J. Epidemiol."},{"issue":"1","key":"10.1016\/j.canep.2017.08.012_bib0185","doi-asserted-by":"crossref","first-page":"219","DOI":"10.1007\/s10549-015-3311-9","article-title":"Antihypertensive medication use and incident breast cancer in women","volume":"150","author":"Devore","year":"2015","journal-title":"Breast Cancer Res. Treat."},{"issue":"8","key":"10.1016\/j.canep.2017.08.012_bib0190","doi-asserted-by":"crossref","first-page":"1438","DOI":"10.1002\/(SICI)1097-0142(19971015)80:8<1438::AID-CNCR11>3.0.CO;2-6","article-title":"Use of calcium channel blockers and breast carcinoma risk in postmenopausal women","volume":"80","author":"Fitzpatrick","year":"1997","journal-title":"Cancer"},{"issue":"3","key":"10.1016\/j.canep.2017.08.012_bib0195","doi-asserted-by":"crossref","first-page":"231","DOI":"10.1007\/s10549-005-9091-x","article-title":"A cohort study of antihypertensive medication use and breast cancer among Danish women","volume":"97","author":"Fryzek","year":"2006","journal-title":"Breast Cancer Res. Treat."},{"issue":"8","key":"10.1016\/j.canep.2017.08.012_bib0200","doi-asserted-by":"crossref","first-page":"581","DOI":"10.1002\/pds.910","article-title":"Breast cancer incidence and use of antihypertensive medication in women","volume":"13","author":"Gonzalez-Perez","year":"2004","journal-title":"Pharmacoepidemiol. Drug Saf."},{"issue":"1","key":"10.1016\/j.canep.2017.08.012_bib0205","doi-asserted-by":"crossref","first-page":"e009147","DOI":"10.1136\/bmjopen-2015-009147","article-title":"Calcium channel blockers and cancer: a risk analysis using the UK clinical practice research datalink (CPRD)","volume":"6","author":"Grimaldi-Bensouda","year":"2016","journal-title":"BMJ Open"},{"key":"10.1016\/j.canep.2017.08.012_bib0210","first-page":"130","article-title":"Long term use of calcium channel blockers and risk of breast cancer development [abstract]","author":"Lam","year":"2014","journal-title":"Circulation"},{"issue":"10","key":"10.1016\/j.canep.2017.08.012_bib0215","doi-asserted-by":"crossref","first-page":"1615","DOI":"10.1007\/s10552-010-9590-x","article-title":"Hypertension, antihypertensive medication use, and breast cancer risk in the California teachers study cohort","volume":"21","author":"Largent","year":"2010","journal-title":"Cancer Causes Control"},{"issue":"1","key":"10.1016\/j.canep.2017.08.012_bib0220","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1007\/s40119-015-0035-1","article-title":"Long-term use of antihypertensive agents and risk of breast cancer: a population-based case-control study","volume":"4","author":"Leung","year":"2015","journal-title":"Cardiol Ther"},{"issue":"7","key":"10.1016\/j.canep.2017.08.012_bib0225","doi-asserted-by":"crossref","first-page":"1504","DOI":"10.1002\/cncr.11663","article-title":"Relation between use of antihypertensive medications and risk of breast carcinoma among women ages 65\u201379 years","volume":"98","author":"Li","year":"2003","journal-title":"Cancer"},{"issue":"17","key":"10.1016\/j.canep.2017.08.012_bib0230","doi-asserted-by":"crossref","first-page":"1629","DOI":"10.1001\/jamainternmed.2013.9071","article-title":"Use of antihypertensive medications and breast cancer risk among women aged 55 to 74 years","volume":"173","author":"Li","year":"2013","journal-title":"JAMA Intern. Med."},{"issue":"3","key":"10.1016\/j.canep.2017.08.012_bib0235","doi-asserted-by":"crossref","first-page":"349","DOI":"10.1001\/archinte.160.3.349","article-title":"Angiotensin-converting enzyme inhibitors, calcium channel blockers, and breast cancer","volume":"160","author":"Meier","year":"2000","journal-title":"Arch. Intern. Med."},{"issue":"1","key":"10.1016\/j.canep.2017.08.012_bib0240","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1007\/s10557-006-6312-4","article-title":"Safety of nifedipine GITS in stable angina: the ACTION trial","volume":"20","author":"Poole-Wilson","year":"2006","journal-title":"Cardiovasc. Drugs Ther."},{"key":"10.1016\/j.canep.2017.08.012_bib0245","first-page":"552","article-title":"Breast cancer risk with long-term use of calcium channel blockers or angiotensin-converting enzyme inhibitors among postmenopausal women [abstract]","volume":"24","author":"Raebel","year":"2015","journal-title":"Pharmacoepidemiol. Drug Saf."},{"issue":"2","key":"10.1016\/j.canep.2017.08.012_bib0250","doi-asserted-by":"crossref","first-page":"365","DOI":"10.1007\/s10552-012-0122-8","article-title":"Use of antihypertensive medications and breast cancer risk","volume":"24","author":"Saltzman","year":"2013","journal-title":"Cancer Causes Control"},{"key":"10.1016\/j.canep.2017.08.012_bib0255","doi-asserted-by":"crossref","first-page":"S1588","DOI":"10.1200\/jco.2015.33.15_suppl.1588","article-title":"The long-term use of calcium channel blockers and the risk of breast cancer [abstract]","volume":"33","author":"Soldera","year":"2015","journal-title":"J. Clin. Oncol."},{"issue":"1","key":"10.1016\/j.canep.2017.08.012_bib0260","doi-asserted-by":"crossref","first-page":"165","DOI":"10.1002\/1097-0142(20000701)89:1<165::AID-CNCR21>3.0.CO;2-G","article-title":"Cancer risk and mortality in users of calcium channel blockers. A cohort study","volume":"89","author":"Sorensen","year":"2000","journal-title":"Cancer"},{"key":"10.1016\/j.canep.2017.08.012_bib0265","doi-asserted-by":"crossref","first-page":"e45","DOI":"10.1097\/01.hjh.0000467465.54504.ae","article-title":"Incidence and prognosis of cancer associated with digoxin and common antihypertensive drugs [abstract]","volume":"33","author":"Lip","year":"2015","journal-title":"J. Hypertens."},{"issue":"11","key":"10.1016\/j.canep.2017.08.012_bib0270","doi-asserted-by":"crossref","first-page":"1039","DOI":"10.1002\/pds.1656","article-title":"Long-term use of antihypertensive drugs and risk of cancer","volume":"17","author":"Assimes","year":"2008","journal-title":"Pharmacoepidemiol. Drug Saf."},{"issue":"1","key":"10.1016\/j.canep.2017.08.012_bib0275","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1097\/00004872-199816010-00017","article-title":"Cancer risk of hypertensive patients taking calcium antagonists","volume":"16","author":"Hole","year":"1998","journal-title":"J. Hypertens."},{"issue":"9051","key":"10.1016\/j.canep.2017.08.012_bib0280","doi-asserted-by":"crossref","first-page":"525","DOI":"10.1016\/S0140-6736(97)80084-0","article-title":"Calcium-channel blockers and risk of cancer","volume":"349","author":"Jick","year":"1997","journal-title":"Lancet"},{"issue":"9281","key":"10.1016\/j.canep.2017.08.012_bib0285","doi-asserted-by":"crossref","first-page":"539","DOI":"10.1016\/S0140-6736(01)05704-X","article-title":"Relation between drug treatment and cancer in hypertensives in the Swedish Trial in Old Patients with Hypertension 2: a 5-year, prospective, randomised, controlled trial","volume":"358","author":"Lindholm","year":"2001","journal-title":"Lancet"},{"issue":"9","key":"10.1016\/j.canep.2017.08.012_bib0290","doi-asserted-by":"crossref","first-page":"2003","DOI":"10.1002\/(SICI)1097-0142(19981101)83:9<2003::AID-CNCR17>3.0.CO;2-3","article-title":"Calcium channel blockers, cancer incidence, and cancer mortality in a cohort of U.S. women: the nurses' health study","volume":"83","author":"Michels","year":"1998","journal-title":"Cancer"},{"issue":"5","key":"10.1016\/j.canep.2017.08.012_bib0295","doi-asserted-by":"crossref","first-page":"1091","DOI":"10.1161\/01.HYP.29.5.1091","article-title":"Cancer risk in users of calcium channel blockers","volume":"29","author":"Olsen","year":"1997","journal-title":"Hypertension"},{"issue":"9026","key":"10.1016\/j.canep.2017.08.012_bib0300","doi-asserted-by":"crossref","first-page":"493","DOI":"10.1016\/S0140-6736(96)04277-8","article-title":"Calcium-channel blockade and incidence of cancer in aged populations","volume":"348","author":"Pahor","year":"1996","journal-title":"Lancet"},{"issue":"13","key":"10.1016\/j.canep.2017.08.012_bib0305","doi-asserted-by":"crossref","first-page":"1000","DOI":"10.1001\/jama.279.13.1000","article-title":"Calcium channel blockers and the risk of cancer","volume":"279","author":"Rosenberg","year":"1998","journal-title":"JAMA"},{"key":"10.1016\/j.canep.2017.08.012_bib0310","first-page":"A9","article-title":"Verapamil and risk of cancer in patients with coronary artery disease. DAVIT Study Group. Danish Verapamil Infarction Trial","volume":"22","author":"Sajadieh","year":"1999","journal-title":"Am. J. Cardiol."},{"issue":"4","key":"10.1016\/j.canep.2017.08.012_bib0315","doi-asserted-by":"crossref","first-page":"594","DOI":"10.1097\/EDE.0000000000000483","article-title":"Use of calcium channel blockers and risk of breast cancer: a population-based cohort study","volume":"27","author":"Azoulay","year":"2016","journal-title":"Epidemiology"},{"issue":"1","key":"10.1016\/j.canep.2017.08.012_bib0320","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1186\/s13058-016-0720-6","article-title":"Long-term use of calcium channel blocking drugs and breast cancer risk in a prospective cohort of US and Puerto Rican women","volume":"18","author":"Wilson","year":"2016","journal-title":"Breast Cancer Res."},{"issue":"8","key":"10.1016\/j.canep.2017.08.012_bib0325","doi-asserted-by":"crossref","first-page":"e0159672","DOI":"10.1371\/journal.pone.0159672","article-title":"The use of antihypertensive medication and the risk of Breast cancer in a case-control study in a Spanish population: the MCC-Spain study","volume":"11","author":"Gomez-Acebo","year":"2016","journal-title":"PLoS One"},{"issue":"9","key":"10.1016\/j.canep.2017.08.012_bib0330","doi-asserted-by":"crossref","first-page":"973","DOI":"10.1016\/j.jclinepi.2003.12.017","article-title":"Misclassification of exposure is high when interview data on drug use are used as a proxy measure of chronic drug use during follow-up","volume":"57","author":"Beiderbeck","year":"2004","journal-title":"J. Clin. Epidemiol."},{"issue":"1","key":"10.1016\/j.canep.2017.08.012_bib0335","first-page":"144","article-title":"African-American ethnicity in epidemiological studies of calcium antagonists in relation to cancer","volume":"12","author":"Zhu","year":"2002","journal-title":"Ethn. Dis."},{"issue":"3","key":"10.1016\/j.canep.2017.08.012_bib0340","first-page":"260","article-title":"Regular medication in women who develop breast cancer: a pilot study","volume":"10","author":"Finn","year":"2001","journal-title":"Breast"},{"issue":"4","key":"10.1016\/j.canep.2017.08.012_bib0345","doi-asserted-by":"crossref","first-page":"643","DOI":"10.1002\/ijc.20758","article-title":"Cancer risk among statin users: a population-based cohort study","volume":"114","author":"Friis","year":"2005","journal-title":"Int. J. Cancer"},{"issue":"9","key":"10.1016\/j.canep.2017.08.012_bib0350","doi-asserted-by":"crossref","first-page":"2462","DOI":"10.1002\/1097-0142(20011101)92:9<2462::AID-CNCR1596>3.0.CO;2-L","article-title":"Angiotensin-converting enzyme inhibitors and the risk of cancer: a population-based cohort study in Denmark","volume":"92","author":"Friis","year":"2001","journal-title":"Cancer"},{"issue":"4","key":"10.1016\/j.canep.2017.08.012_bib0355","doi-asserted-by":"crossref","first-page":"589","DOI":"10.1530\/EJE-12-0053","article-title":"Incidence and predictors of all-cause and site-specific cancer in type 2 diabetes: the Fremantle Diabetes Study","volume":"167","author":"Magliano","year":"2012","journal-title":"Eur. J. Endocrinol."},{"issue":"1","key":"10.1016\/j.canep.2017.08.012_bib0360","doi-asserted-by":"crossref","first-page":"180","DOI":"10.1111\/j.1365-2125.2012.04170.x","article-title":"Long term use of drugs affecting the renin-angiotensin system and the risk of cancer: a population-based case-control study","volume":"74","author":"Hallas","year":"2012","journal-title":"Br. J. Clin. Pharmacol."},{"key":"10.1016\/j.canep.2017.08.012_bib0365","doi-asserted-by":"crossref","first-page":"159","DOI":"10.1016\/j.ijcard.2015.04.171","article-title":"Carvedilol use and specific cancer risk in the population with hypertension: reply","volume":"190","author":"Lin","year":"2015","journal-title":"Int. J. Cardiol."},{"issue":"6","key":"10.1016\/j.canep.2017.08.012_bib0370","doi-asserted-by":"crossref","first-page":"1369","DOI":"10.1002\/(SICI)1097-0142(19990315)85:6<1369::AID-CNCR21>3.0.CO;2-5","article-title":"Incidence of cancer in postmyocardial infarction patients treated with short-acting nifedipine and diltiazem","volume":"85","author":"Kanamasa","year":"1999","journal-title":"Cancer"},{"issue":"10022","key":"10.1016\/j.canep.2017.08.012_bib0375","doi-asserted-by":"crossref","first-page":"957-","DOI":"10.1016\/S0140-6736(15)01225-8","article-title":"Blood pressure lowering for prevention of cardiovascular disease and death: a systematic review and meta-analysis","volume":"387","author":"Ettehad","year":"2016","journal-title":"Lancet"},{"issue":"9754","key":"10.1016\/j.canep.2017.08.012_bib0380","doi-asserted-by":"crossref","first-page":"1741","DOI":"10.1016\/S0140-6736(10)61543-7","article-title":"Long-term effect of aspirin on colorectal cancer incidence and mortality: 20-year follow-up of five randomised trials","volume":"376","author":"Rothwell","year":"2010","journal-title":"Lancet"}],"container-title":["Cancer Epidemiology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S187778211730139X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S187778211730139X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2019,10,2]],"date-time":"2019-10-02T22:39:57Z","timestamp":1570055997000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S187778211730139X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,10]]},"references-count":76,"alternative-id":["S187778211730139X"],"URL":"https:\/\/doi.org\/10.1016\/j.canep.2017.08.012","relation":{},"ISSN":["1877-7821"],"issn-type":[{"value":"1877-7821","type":"print"}],"subject":[],"published":{"date-parts":[[2017,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Calcium channel blockers and breast cancer incidence: An updated systematic review and meta-analysis of the evidence","name":"articletitle","label":"Article Title"},{"value":"Cancer Epidemiology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.canep.2017.08.012","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2017 Elsevier Ltd. All rights reserved.","name":"copyright","label":"Copyright"}]}}